Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_014501595db6d2fb77c02991635ce53b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6081e36fba5289c23c4a16329798821e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d56d035b4b713bafee04e3fb0b4d1df |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
filingDate |
2013-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13d4f2b8b61c4d8c677f341d5b82791d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b1ad91f8ca4af8e4339924c35966c8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a7b4f3ff61434fd162c59450b743470 |
publicationDate |
2014-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2014106011-A1 |
titleOfInvention |
Production and extraction of microrna precursor as drug for cancer therapy |
abstract |
This invention generally relates to a composition for developing novel anti-cancer drugs and/or vaccines and producing microRNA precursor (pre-miRNA) and/or its shRNA homologues/mimics/derivatives, and a method thereof. The present invention also relates to a use of a composition in producing novel prokaryote-produced microRNA precursor (pro-miRNA) capable of being delivered into human cells and processed by the cells into microRNA-like effectors to elicit specific silencing effects on certain targeted oncogenes, subsequently leading to a therapeutic result of tumor suppression and cancer therapy. Specifically, the method of the present invention includes inducing an expression of the pre-miRNA/pro-miRNAs, particularly human pre-miR-302, in prokaryotes through pol-2 or pol-2-like RNA promoter. Most importantly, the composition of the present invention is further a novel pre-miRNA-based drug that is capable of reprogramming the malignant properties of high-grade human liver cancers into a low-grade benign or even relatively normal stage - a mechanism called "Cancer Reversion". |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018535684-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108431227-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017095489-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017095458-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016191604-A1 |
priorityDate |
2012-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |